The Motley Fool

The Avacta share price (AVCT) has climbed 1,400%. Here’s what I’d do now

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Coronavirus 2019-nCoV Blood Samples Medical Concept
Image source: Getty Images

Companies involved in Covid-19 testing have done well during the pandemic — and that includes Avacta Group (LSE: AVCT). The company released an update on its SARS-CoV-2 antigen lateral flow test on Monday, and the shares picked up 4% on the day. But that’s only a small part of the story — the Avacta share price has climbed a staggering 1,400% since the beginning of 2020.

We do need to see that in perspective, mind. Before Covid-19 turned up, there obviously wasn’t much call for Covid-19 testing. And Avacta was getting along with its cancer therapies and diagnostics. So a big boost to the Avacta share price since then is perhaps not surprising. But can it be sustained, and is there more growth to come?

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic… and with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. And if you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio.

Click here to claim your free copy now!

First, let’s look at the latest news. The company mentions “recently announced data from a clinical study on 98 positive COVID-19 samples that demonstrate excellent performance in identifying the SARS-CoV-2 virus across a broad range of viral loads“. Avacta goes on to say it “expects to receive confirmation of the registration of the AffiDX in-vitro diagnostic device in the coming days, which will allow the group to immediately place the test on the market“.

Better than the competition

Chief executive Dr Alastair Smith added that, compared to two other commercially available lateral flow antigen tests, “the AffiDX test had better clinical sensitivity across the range of Ct values tested and, in particular, at lower viral loads“.

I take two immediate thoughts from that. The first is that the Avacta share price has gone on its sky-high, 1,000%+, ride even before the company had a saleable Covid-19 test. Wow! But secondly, if the Avacta test works better at lower viral loads, it could turn out to be very important indeed. Current lateral flow tests are not as accurate as laboratory tests that can take up to a couple of days to perform.

But where will the Avacta Group share price go for the rest of 2021 and beyond? Fellow Motley Fool writer Andy Ross recently suggested we could see another strong run in May. He could be right. I wouldn’t be surprised to see another leap upwards when the AffiDX test gets its expected approval. So would I buy the shares now?

Well, if ever there was a case where ‘past performance is no guide to future performance’ was apt, this is surely it. And I would not invest based solely on the short-term performance of anything. Saying that, there’s a good chance that Covid-19 will be with us long-term, just like influenza. And I can see demand for Covid-19 testing continuing for many more years.

Avacta share price valuation

But there’s another thing that puts me off high-flying growth shares like this. Avacta reported an operating loss in 2020, largely due to R&D spend. That makes it impossible for me to put any kind of rational valuation on the company. Is today’s price good value compared to future profits? Or is the Avacta share price pumped up much higher than it’s worth?

I have no idea, and I’ll keep away from the risk that comes with such uncertainty. But for any brave investors taking the chance, I wish them well.

FREE REPORT: Why this £5 stock could be set to surge

Are you on the lookout for UK growth stocks?

If so, get this FREE no-strings report now.

While it’s available: you'll discover what we think is a top growth stock for the decade ahead.

And the performance of this company really is stunning.

In 2019, it returned £150million to shareholders through buybacks and dividends.

We believe its financial position is about as solid as anything we’ve seen.

  • Since 2016, annual revenues increased 31%
  • In March 2020, one of its senior directors LOADED UP on 25,000 shares – a position worth £90,259
  • Operating cash flow is up 47%. (Even its operating margins are rising every year!)

Quite simply, we believe it’s a fantastic Foolish growth pick.

What’s more, it deserves your attention today.

So please don’t wait another moment.

Get the full details on this £5 stock now – while your report is free.

Alan Oscroft has no position in any of the shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.